Status:
COMPLETED
Gamma-linolenic Acid Supplementation Study
Lead Sponsor:
Virta Health
Conditions:
Weight Trajectory
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight rega...
Detailed Description
The primary purpose of this research is to determine if GLA supplementation reduces weight regain over 24 months in Virta Health patients. The secondary purpose is to determine the effect of GLA supp...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 yrs
- Patients referred to Virta Health by employers or insurers
- Weight loss greater than or equal to 7% of initial weight and current BMI \> 25 kg/m2
- Willing to take 3 supplement capsules daily
- Able to understand study procedures and willing to provide informed consent
- English-speaking
Exclusion
- Patients who are pregnant or lactating
- Patients who are taking or are prescribed orlistat
Key Trial Info
Start Date :
July 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2023
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT04481724
Start Date
July 22 2020
End Date
September 15 2023
Last Update
April 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virta Health
San Francisco, California, United States, 94105